Biochemical Role of Long Non-coding RNA MALAT 1 and Serum Tumor Necrosis Factor Alpha in Bronchial Asthma Patients.

NCT06459895 | Completed

• 1 other identifier: Soh-Med-24-05-03PD
• Study Type: observational
• Target: 194
• Locations: 1 country
• Sites: 1

Brief Summary

Bronchial asthma affects more than a quarter of a billion people worldwide. It is responsible for over 1000 deaths a day, of which the majority are preventable (Levy, 2015). Asthma is a common heterogeneous disease characterized by chronic airway inflammation. It is defined by the history of variable respiratory symptoms, such as shortness of breath, chest tightness, wheezes, and cough, together with variable expiratory airflow limitation. Airflow limitation may later become persistent (GINA, 2023). The diagnosis of asthma is based on the history of these characteristic symptoms and evidence of variable expiratory airflow limitation from bronchodilator reversibility testing or other tests (GINA, 2023).

Conditions

Bronchial Asthma

Outcome Measures

Primary Outcomes (1)

• Long non-coding MALAT1 gene expression assay:

  Gene expression assay by RT-PCR reaction

  2 MONTHS

Secondary Outcomes (1)

• TNF-alpha

  2 MONTHS

Study Arms (2)

diseased group

bronchial asthma diseased group

Diagnostic Test: Long non-coding MALAT1 gene expression assay:

control group

healthy person

Diagnostic Test: Long non-coding MALAT1 gene expression assay:

Interventions

Long non-coding MALAT1 gene expression assay: DIAGNOSTIC_TEST

RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction

control group; diseased group

Eligibility Criteria

• Age: 15 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

The study was case control had included 97 asthma patients and 97 healthy controls. The asthmatic patients will cautiously select from those attending the respiratory consultant clinics at Sohag University Hospital diagnosed with asthma (with no history of respiratory infections) PFT was performed with a spirometer (PHILIPS). The primary purpose of it was to confirm the diagnosis of asthma. Pre- and post-bronchodilator spirometer measurements will be performed in all study subjects and forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) values and FEV1/FVC ratio will be

You may qualify if:

• All patients were admitted to Sohag University Hospital, chest department DIAGNOSED AS BRONCHIAL ASTHMA

You may not qualify if:

• Patients with malignancies, major trauma or surgery, and acute or chronic infectious diseases were excluded.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University Hospital

Sohag, Egypt

Location

Related Publications (3)

• Choi JP, Kim YS, Kim OY, Kim YM, Jeon SG, Roh TY, Park JS, Gho YS, Kim YK. TNF-alpha is a key mediator in the development of Th2 cell response to inhaled allergens induced by a viral PAMP double-stranded RNA. Allergy. 2012 Sep;67(9):1138-48. doi: 10.1111/j.1398-9995.2012.02871.x. Epub 2012 Jul 5.

  PMID: 22765163 BACKGROUND

• Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015 Mar;11(1):14-24. doi: 10.1183/20734735.008914.

  PMID: 26306100 BACKGROUND

• Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, Elias JA. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004 Oct;10(10):1095-103. doi: 10.1038/nm1105. Epub 2004 Sep 19.

  PMID: 15378055 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Ten ml of blood was collected from patients by venipuncture. Samples were divided into two parts. The first part was added to EDTA (Ethylenediamine-tetra acetic acid) tube, until the extraction of RNA

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD in Medical Biochemistry

Study Record Dates

• First Submitted: June 10, 2024
• First Posted: June 14, 2024
• Study Start: April 16, 2024
• Primary Completion: June 10, 2024
• Study Completion: June 10, 2024
• Last Updated: June 14, 2024

Record last verified: 2024-06

Locations

EG (1)